Cytek Biosciences Inc (CTKB)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | -13,638 | 3,833 | 7,679 |
| Long-term debt | US$ in thousands | — | — | — |
| Total stockholders’ equity | US$ in thousands | 393,064 | 425,546 | 405,385 |
| Return on total capital | -3.47% | 0.90% | 1.89% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $-13,638K ÷ ($—K + $393,064K)
= -3.47%
The return on total capital for Cytek Biosciences Inc has shown a declining trend over the past three years. In 2021, the return on total capital was 1.89%, indicating that for every dollar of total capital employed by the company, it generated a return of 1.89%. However, this figure decreased to 0.90% in 2022 and further dropped to -3.47% in 2023, signifying a notable deterioration in the company's ability to generate returns relative to its total capital base.
The negative return on total capital in 2023 suggests that Cytek Biosciences Inc experienced a loss on its total capital, which could be a cause for concern regarding the company's financial performance and efficiency in utilizing its capital resources effectively to generate profits. Further analysis would be required to understand the specific factors contributing to this decline and to determine potential strategies for improving the company's return on total capital in the future.
Peer comparison
Dec 31, 2023